Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

(2021) Dmytro Trukhin et al.   BIODRUGS

Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)

(2021) Konstantinos Syrigos et al.   BIODRUGS

IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain

(2021) Naoyuki Nogami et al.   Journal of Thoracic Oncology

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

(2020) Nasser H. Hanna et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer

(2020) Martin Reck et al.   LUNG CANCER

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study

(2019) Nicholas Thatcher et al.   CLINICAL CANCER RESEARCH

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

(2019) Weiting Liao et al.   JOURNAL OF MEDICAL ECONOMICS

A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males

(2019) Sang-Heon Cho et al.   BIODRUGS

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

(2019) Niels Reinmuth et al.   BIODRUGS

Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs

(2019) Francesca Civoli et al.   AAPS Journal

Bevacizumab biosimilars: scientific justification for extrapolation of indications

(2018) Barbara Melosky et al.   Future Oncology

Anti-Angiogenics: Their Value in Lung Cancer Therapy

(2018) Melanie Janning et al.   Oncology Research and Treatment

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Cost–effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access

(2018) Pedro Aguiar et al.   Immunotherapy

An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements

(2017) Christian Buske et al.   Future Oncology

Bevacizumab: A Review of Its Use in Advanced Cancer

(2014) Gillian M. Keating   DRUGS

The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review

(2013) Limor Amit et al.   PLoS One

A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer

(2011) Bernardo Goulart et al.   VALUE IN HEALTH

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY